Teclistamab – March 2026

Solution for subcutaneous injection 30 mg in 3 mL, Solution for subcutaneous injection 153 mg in 1.7 mL

  • Brand names:
    • Tecvayli®
  • Pharmaceutical Company:
    • JANSSEN-CILAG PTY LTD
  • Condition/Indication: Relapsed or refractory multiple myeloma (RRMM)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026